Positron Emission Tomography in Prostate Cancer
Positron Emission Tomography in Prostate Cancer
批准号:
7284811
负责人:
FARROKH DEHDASHTI
金额:
$29.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2009-06-30
关键词:
AcetatesAdjuvant TherapyAffectAftercareBiopsyClinicalDataDetectionDiseaseGleason Grade for Prostate CancerGoalsGrantHealthHormonalImage AnalysisLaparoscopic Surgical ProceduresLeadMalignant neoplasm of prostateMethodsMorbidity - disease rateNeoplasm MetastasisOntologyOperative Surgical ProceduresPatientsPerformancePhysiciansPopulationPositron-Emission TomographyPredictive ValueProstateRadiation therapyRadical ProstatectomyRadiopharmaceuticalsRecurrenceResearchResearch DesignResearch PersonnelRiskRoleStagingStandards of Weights and MeasuresTimeTreatment ProtocolsWorkbaseexperienceimprovedlymph nodesmenpreventprognostictumor
中文摘要
描述(由申请人提供):
该项目的主要目标是确定采用放射性药物C-11醋酸盐(AC-PET)的正电子发射断层扫描在中高危前列腺癌患者中的价值,这些患者是通过根治性前列腺切除术或放射治疗进行治愈性治疗的候选人,因为标准临床和成像评估对肿瘤扩散到前列腺以外呈阴性。具体目标如下:1.确定AC-PET在改变初始患者管理中的作用; 2.确定AC-PET在预测复发中的价值; 3.通过与活检比较,评估AC-PET检测淋巴结的性能。研究设计:该研究包括两组共285名患者,他们计划接受治愈性治疗,两组患者都将在治疗前接受AC-PET成像。对于手术组,如果PET检查结果为前列腺外疾病阴性,则将继续治疗,并对患者进行随访,以寻找复发的证据。如果PET检查呈阳性,将鼓励转诊医生进行确证性研究,这可能导致治疗的改变。放射治疗组的所有患者将接受标准治疗,然后随访复发的证据。手术患者的淋巴结活检结果将与PET结果相关联,以计算AC-PET的阳性和阴性预测值。预期结果:AC-PET将导致至少10%的手术患者取消根治性乳房切除术。与基于临床分期、PSA和格里森评分的传统方法相比,预计AC-PET将显着提高复发的预测。当与病理学数据相关时,AC-PET的预测价值应该很高。健康相关性:如果该项目成功,将对作为治愈性治疗候选人的中高危前列腺癌患者的管理产生重大影响。在其中一些患者中,PET扫描阳性将导致取消计划的手术,使这些患者免于根治性手术的发病率,同时允许其中一些患者接受更适当的激素治疗。PET还可以提供重要的预后信息,这些信息可能影响早期辅助治疗以延迟或预防复发的决策。
英文摘要
DESCRIPTION (provided by applicant):
The primary goal of this project is determination of the value of positron emission tomography employing the radiopharmaceutical C-11 acetate (AC-PET) in patients with medium- and high-risk prostate cancer who are candidates for treatment with curative intent by radical prostatectomy or radiation therapy because the standard clinical and imaging evaluation was negative for tumor spread beyond the prostate. The following specific aims will be pursued: 1. Determine the role of AC-PET in changing initial patient management; 2. Determine the value of AC-PET in predicting recurrence; 3. Assess the performance of AC-PET for detection of lymph nodes by comparison with biopsy. Study Design: The study includes a total of 285 patients in two groups who are scheduled for treatment with curative intent, both of whom will undergo AC-PET imaging prior to treatment. For the surgery group, if the PET examination is negative for disease outside the prostate gland, the treatment will proceed and the patient will be followed for evidence of recurrence. If the PET examination is positive, the referring physician will be encouraged to undertake confirmatory studies, which may lead to a change in therapy. All patients in the radiation therapy group will undergo the standard treatment, and they will then be followed for evidence of recurrence. The lymph node biopsy results in the surgery patients will be correlated with the PET findings to compute the positive and negative predictive values of AC-PET. Anticipated Results: AC-PET will lead to cancellation of radical prostatectomy in at least 10% of the surgical patients. It is also expected that AC-PET will significantly improve the prediction of recurrence compared with conventional methods based on clinical stage, PSA and Gleason score. The predictive value of AC-PET should be high when correlated with the pathological data. Health Relevance: If this project is successful, it will have a significant impact on the management of patients with moderate- and high-risk prostate cancer who are candidates for curative treatment. In some of these patients, a positive PET scan will lead to cancellation of planned surgery, sparing these men the morbidity of radical surgery while permitting some of them to receive more appropriate hormonal treatment. PET may also contribute significant prognostic information that may affect the decision to administer early adjuvant therapy to delay or prevent recurrence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FFNP-PET as a predictive biomarker of response to endocrine therapy approaches in advanced breast cancer
-
批准号:10504739
-
项目类别:
-
资助金额:$64.72万
-
财政年份:2022
-
负责人:FARROKH DEHDASHTI
-
依托单位:
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
-
批准号:10534151
-
项目类别:
-
资助金额:$16.85万
-
财政年份:2019
-
负责人:FARROKH DEHDASHTI
-
依托单位:
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
-
批准号:10318589
-
项目类别:
-
资助金额:$59.19万
-
财政年份:2019
-
负责人:FARROKH DEHDASHTI
-
依托单位:
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
-
批准号:10078604
-
项目类别:
-
资助金额:$59.73万
-
财政年份:2019
-
负责人:FARROKH DEHDASHTI
-
依托单位:
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB
-
批准号:8635832
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2014
-
负责人:FARROKH DEHDASHTI
-
依托单位:
A FEASIBILITY PET STUDY OF HER2 RECEPTORS IN BREAST CANCER USING 89ZR-TRASTUZUMAB
-
批准号:8788511
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2014
-
负责人:FARROKH DEHDASHTI
-
依托单位:
Positron Emission Tomography in Prostate Cancer
-
批准号:7486861
-
项目类别:
-
资助金额:$29.92万
-
财政年份:2003
-
负责人:FARROKH DEHDASHTI
-
依托单位:
CLINICAL ASSESSMENT OF TUMOR HYPOXIA WITH PET
-
批准号:2842143
-
项目类别:
-
资助金额:$15.34万
-
财政年份:1999
-
负责人:FARROKH DEHDASHTI
-
依托单位:
CLINICAL ASSESSMENT OF TUMOR HYPOXIA WITH PET
-
批准号:6173963
-
项目类别:
-
资助金额:$15.35万
-
财政年份:1999
-
负责人:FARROKH DEHDASHTI
-
依托单位:
IN VIVO ASSESSMENT OF TUMOR RECEPTOR LEVELS USING PET
-
批准号:2330763
-
项目类别:
-
资助金额:$26.85万
-
财政年份:1989
-
负责人:FARROKH DEHDASHTI
-
依托单位:
IN VIVO ASSESSMENT OF TUMOR RECEPTOR LEVELS USING PET
-
批准号:2871737
-
项目类别:
-
资助金额:$27.32万
-
财政年份:1989
-
负责人:FARROKH DEHDASHTI
-
依托单位:
IN VIVO ASSESSMENT OF TUMOR RECEPTOR LEVELS USING PET
-
批准号:2092983
-
项目类别:
-
资助金额:$26.54万
-
财政年份:1989
-
负责人:FARROKH DEHDASHTI
-
依托单位:
IN VIVO ASSESSMENT OF TUMOR RECEPTOR LEVELS USING PET
-
批准号:2654050
-
项目类别:
-
资助金额:$27.08万
-
财政年份:1989
-
负责人:FARROKH DEHDASHTI
-
依托单位:
海外基金